Kim Horslev-Petersen
Overview
Explore the profile of Kim Horslev-Petersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1756
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dijkshoorn B, Hansildaar R, Vedder D, Soutari N, Rudin A, Nordstrom D, et al.
RMD Open
. 2024 Dec;
10(4.
PMID: 39740931
Objectives: To assess the effect of treatment on haemostatic parameters in patients with early rheumatoid arthritis (RA). Methods: Patients with newly diagnosed RA started methotrexate and were randomised to additional...
2.
Vasileiadis G, Zhang Y, Fatima T, van Vollenhoven R, Lampa J, Gudbjornsson B, et al.
ACR Open Rheumatol
. 2024 Nov;
7(1):e11756.
PMID: 39496558
Objective: The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA). Methods: This...
3.
Scheffler J, Drevinge C, Lindholm C, Gjertsson I, Lend K, Hetland M, et al.
ACR Open Rheumatol
. 2024 Oct;
7(1):e11742.
PMID: 39411912
Objective: The high prevalence of osteoporosis in rheumatoid arthritis (RA) is due to inflammation that stimulates differentiation of osteoclasts, a process involving circulating monocytes and T cell-derived factors. The aim...
4.
Lend K, Lampa J, Padyukov L, Hetland M, Heiberg M, Nordstrom D, et al.
Ann Rheum Dis
. 2024 Jul;
83(12):1657-1665.
PMID: 39079894
Objectives: To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active...
5.
Dubovyk V, Vasileiadis G, Fatima T, Zhang Y, Kapetanovic M, Kastbom A, et al.
RMD Open
. 2024 Apr;
10(2).
PMID: 38580350
Objective: This report from the NORD-STAR (Nordic Rheumatic Diseases Strategy Trials and Registries) trial aimed to determine if obesity is associated with response to conventional and biological antirheumatic treatment in...
6.
Moller-Bisgaard S, Horslev-Petersen K, Ornbjerg L, Ejbjerg B, Hetland M, Moller J, et al.
RMD Open
. 2024 Mar;
10(1).
PMID: 38490697
Objective: To investigate whether a 2-year MRI treat-to-target strategy targeting the absence of osteitis combined with clinical remission, compared with a conventional treat-to-target strategy targeting clinical remission only (IMAGINE-rheumatoid arthritis...
7.
Liu J, Idborg H, Korotkova M, Lend K, van Vollenhoven R, Lampa J, et al.
Arthritis Res Ther
. 2024 Mar;
26(1):61.
PMID: 38444034
Background: Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient's response to these therapies. Prostanoids, encompassing prostaglandins,...
8.
Lend K, van Vollenhoven R, Lampa J, Hetland M, Haavardsholm E, Nordstrom D, et al.
Lancet Rheumatol
. 2024 Jan;
4(10):e688-e698.
PMID: 38265967
Background: Rheumatoid arthritis is a chronic inflammatory disease with a well-recognised female preponderance. In this post-hoc analysis of the NORD-STAR trial, we aimed to examine sex differences in remission rates...
9.
Lend K, Koopman F, Lampa J, Jansen G, Hetland M, Uhlig T, et al.
Arthritis Rheumatol
. 2023 Oct;
76(3):363-376.
PMID: 37846618
Objective: We investigated methotrexate safety and the influence of dose on efficacy outcomes in combination with three different biologic treatments and with active conventional treatment (ACT) in early rheumatoid arthritis...
10.
Ostergaard M, van Vollenhoven R, Rudin A, Hetland M, Heiberg M, Nordstrom D, et al.
Ann Rheum Dis
. 2023 Jul;
82(10):1286-1295.
PMID: 37423647
Background: The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different...